Bafna Pharmaceuticals Ltd - Stock Valuation and Financial Performance

BSE: 532989 | NSE: BAFNAPH | Pharmaceuticals & Drugs | Small Cap

Bafna Pharma Share Price

71.95 0.00 0.00%
as on 20-Feb'25 16:59

DeciZen - make an informed investing decision on Bafna Pharma

Overall Rating
M-Cap below 500cr. High Risk from low Liquidity Bole Toh

1. Quality

2. Valuation

Fair

3. Price Trend

Bafna Pharmaceuticals stock performance -

P/E Ratio (SA):
40.63
Market Cap:
174.6 Cr.
52-wk low:
67.8
52-wk high:
112.2

Is Bafna Pharmaceuticals Ltd an attractive stock to invest in?

1. Is Bafna Pharmaceuticals Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Bafna Pharmaceuticals Ltd is a below average quality company.

2. Is Bafna Pharmaceuticals Ltd undervalued or overvalued?

The key valuation ratios of Bafna Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Bafna Pharmaceuticals Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Bafna Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Bafna Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Bafna Pharmaceuticals Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
ROCE % 12.6%-0%-6%-7%-20.9%-3%10.6%8.4%16.1%9.6%-
Value Creation
Index
-0.1-1.0-1.4-1.5-2.5NA-0.2-0.40.2-0.3-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 14385.36547.243.642.571.285.1115152148
Sales YoY Gr.--40.1%-23.9%-27.4%-7.5%-2.7%67.7%19.6%35.5%32.2%-
Adj EPS 4.4-6.6-10.1-15.9-8.3-8.42.42.14.32.61.8
YoY Gr.--249.8%NANANANANA-10.6%102.4%-39.1%-
BVPS (₹) 38.431.52217.18.8-18.62426.231.134.235.4
Adj Net
Profit
8.2-12.2-18.8-37.7-19.7-25.6510.16.14
Cash Flow from Ops. 9.5-319.8-7.1-1.1-34.3-13.69.759.5-
Debt/CF from Ops. 6.7-27.14.2-6.6-42.2-0.1-11.14.62.6-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 0.8%28.4%28.9%32.2%
Adj EPS -5.7%NA3.3%-39.1%
BVPS-1.3%31.2%12.5%10.1%
Share Price 10.4% 73% -18.5% -20.1%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
Return on
Equity %
11.6-18.7-35.9-88.2-64.4-5.510.38.414.985.2
Op. Profit
Mgn %
183.8-8-74.4-29.8314.51413.67.37.4
Net Profit
Mgn %
5.7-14.4-28.9-80-45.2-4.77.85.88.742.9
Debt to
Equity
0.91.421.22.2-0.70.20.20.30.3-
Working Cap
Days
33649060372168245919321220820893
Cash Conv.
Cycle
1522472902363134074817942

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 28.88%

Return on Equity has declined versus last 3 years average to 5.20%

Sales growth is not so good in last 4 quarters at -1.70%

Latest Financials - Bafna Pharmaceuticals Ltd.

Standalone Consolidated
TTM EPS (₹) 1.8 -10.5
TTM Sales (₹ Cr.) 148 42.5
BVPS (₹.) 35.4 0
Reserves (₹ Cr.) 60 -7
P/BV 2.09 0.00
PE 40.63 0.00
From the Market
52 Week Low / High (₹) 67.80 / 112.20
All Time Low / High (₹) 4.65 / 195.95
Market Cap (₹ Cr.) 175
Equity (₹ Cr.) 23.7
Face Value (₹) 10
Industry PE 37.5

Quarterly Results

 Mar'24 YoY Gr. Rt. %Jun'24 YoY Gr. Rt. %Sep'24 YoY Gr. Rt. %Dec'24 YoY Gr. Rt. %
Sales (₹ Cr.) 41.4 -233.3 -20.640.3 -0.933.2 16.7
Adj EPS (₹) 0.6 -72.7-0.2 -107.51.1 5.70.4 N/A
Op. Profit Mgn % 6.98 -1106 bps3.64 -1136 bps9.40 -44 bps9.23 1653 bps
Net Profit Mgn % 3.52 -919 bps-1.45 -1659 bps6.49 38 bps2.88 1323 bps

Management X-Ray of Bafna Pharma:

Shareholding Pattern

JavaScript chart by amCharts 3.21.5
JavaScript chart by amCharts 3.21.5Promoters:88.3%Institutions:0%Non-Institutions:11.7%

Promoter's Holding & Share Pledging

JavaScript chart by amCharts 3.21.5Sep22Dec22Mar23Jun23Sep23Dec23Mar24Jun24Sep24Dec240%20%40%60%80%100%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Bafna Pharma

MRP
spaceLock icon
MOS
spaceLock icon%
DP
spaceLock icon
Base EPS
spaceLock icon
DPS
spaceLock icon
MRP: ₹ 0
DP: ₹0
Base EPS ₹:
DPS ₹:
MOS (%):
Expected EPS Growth Rate:
0%
Base 0%
50%
Expected Rate of Return:
0%
Base 0%
50%
Future PE:
0
Base 0
200
YTD 1Y 3Y 5Y 10Y Max
YTD 1Y 3Y 5Y 10Y Max
YTD 1Y 3Y 5Y 10Y Max
YTD 1Y 3Y 5Y 10Y Max

Event Update

Login/Register to view analysis.

Analyst's Notes

No data found!

Key Ratios of Bafna Pharma

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Company Name CMP(₹)
Change ₹(%)
Market Cap
Net Sales (₹ Cr.)
Latest EPS (₹)
Net Profit Margin %
Latest P/E
Latest P/BV
Alembic Pharma 802.8 -10.6 (-1.3%) Small Cap 6,229 30.8 9.6 26.4 3.2
Laurus Labs 521.1 -15.4 (-2.9%) Small Cap 5,041 3.7 3.1 144.5 6.9
Piramal Pharma 208.6 -9.5 (-4.3%) Small Cap 4,390 5.2 8.4 42.1 4.1
Ajanta Pharma 2,607.3 -63.1 (-2.4%) Small Cap 4,209 71.9 19 37.2 8.5
Gland Pharma 1,524.3 3.9 (0.3%) Small Cap 4,167 68.1 24.8 22.3 2.7
Natco Pharma 797.8 4.8 (0.6%) Small Cap 3,999 104.1 34.5 7.6 2
Granules India 509 -18.4 (-3.5%) Small Cap 3,755 13.3 11.7 39.7 3.9
Emcure Pharma 996.8 5.2 (0.5%) Small Cap 3,498 8.5 4.4 116.8 6.5
JB Chem & Pharma 1,605.5 -25 (-1.5%) Small Cap 3,299 40.4 16.1 40.4 7.7
Sanofi India 5,076.8 -91.3 (-1.8%) Small Cap 2,851 184.4 20.8 28 15.5
Shows rows:

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Sales14385654744427185115152
Operating Expenses 11783708257416173100141
Manufacturing Costs1410810111114131420
Material Costs81625033241632406387
Employee Cost 1067791012151619
Other Costs 12463113446715
Operating Profit 253-5-35-13110121611
Operating Profit Margin (%) 17.8%3.3%-8.0%-74.4%-30.0%2.9%14.5%14.0%13.6%7.3%
Other Income 11131001234
Interest 1212117201122
Depreciation 5444334555
Exceptional Items -3000000-200
Profit Before Tax 6-13-19-14-18-265127
Tax 00-12200000
Profit After Tax 6-12-18-16-20-265117
PAT Margin (%) 4.3%-14.3%-28.4%-34.9%-45.2%-4.4%8.2%6.1%9.8%4.8%
Adjusted EPS (₹)3.3-6.5-9.9-7.0-8.3-7.92.52.24.83.1
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24

Equity and Liabilities

Shareholders Fund 7259414121-457627381
Share Capital 1919192424224242424
Reserves 53412217-3-733385057
Minority Interest0000000000
Debt6480824746313102021
Long Term Debt1035392323335811
Short Term Debt534543232301051210
Trade Payables35302328391311122835
Others Liabilities 15152013146076711
Total Liabilities 185185167128121718690130148

Fixed Assets

Gross Block70727273737480889599
Accumulated Depreciation22252933363944495459
Net Fixed Assets49474340373536394040
CWIP 00000010212
Investments 1818181100000
Inventories1516171191115202230
Trade Receivables8368542425610154145
Cash Equivalents 2333382081
Others Assets17333248451023161719
Total Assets 185185167128121718690130148

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Cash Flow From Operating Activity 9-320-7-1-34-141059
PBT 6-13-19-14-18-265127
Adjustment -251515-205-204688
Changes in Working Capital 30-6242712-12-23-1-14-5
Tax Paid -2000000000
Cash Flow From Investing Activity 56-1-1438433-5-7-7-15
Capex -8-20470-1-6-8-7-15
Net Investments 15000000000
Others 491-14-943411-10
Cash Flow From Financing Activity -664-5-31-2712-510-1
Net Proceeds from Shares -1704120550000
Net Proceeds from Borrowing -11254-160-203-5121
Interest Paid -12-12-11-7-2000-2-2
Dividend Paid 0000000000
Others -26-8-2-200-2810000
Net Cash Flow 000006-7-28-6
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Ratios
ROE (%)9.22-18.69-37.05-40.37-64.36N/A22.268.7916.759.52
ROCE (%)12.56-0.04-5.98-6.97-20.9N/A10.628.4216.129.56
Asset Turnover Ratio0.70.470.380.320.350.440.90.961.051.1
PAT to CFO Conversion(x)1.5N/AN/AN/AN/AN/A-2.3320.451.29
Working Capital Days
Receivable Days225319335302205133405288104
Inventory Days536791106838969776762
Payable Days167191197280513586134106118134

Bafna Pharmaceuticals Ltd Stock News

Bafna Pharmaceuticals Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Bafna Pharma on 20-Feb-2025 16:59 is ₹71.95.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 20-Feb-2025 16:59 the market cap of Bafna Pharma stood at ₹174.6.
The latest P/E ratio of Bafna Pharma as of 20-Feb-2025 16:59 is 40.63.
The latest P/B ratio of Bafna Pharma as of 20-Feb-2025 16:59 is 2.09.
The 52-week high of Bafna Pharma is ₹112.2 and the 52-week low is ₹67.80.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Bafna Pharma is ₹148.2 ( Cr.) .

About Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals was incepted by Bafna Mahaveer Chand in 1981 as a proprietary concern. It was converted into a public limited company on 28th march 1995. The company started its own manufacturing unit in October 1984.

Bafna Pharmaceuticals started its production with tablets facility and subsequently added capsule and oral syrup facilities respectively. BAFNA always focused on institutional and generic supply to keep its production line busy. It also concentrated on registering its products in the international market.

The present manufacturing facilities of BAFNA is set up at Chennai. The facility for producing Betalactam products was constructed in the year 2001 in a separate block.

It acquired 2.65 acres of factory land in Grantylon village, near Chennai to expand its operations to regulated market like US and UK and also to manufacture its own products.

The company’s vision is to become a leading professionally run global pharma company setting standards across the pharma value chain.

Product Range:

  • Antibacterials
  • Antipyretics
  • Antconvulsants
  • Anxiolytics
  • Pain management
  • Anthelmintics
  • Antifungal
  • Appetite stimulants
  • Antidiarrhoeals
  • Antiemetics
  • Hypnotics
  • Antacids and antiulcerants
  • Vitamin and dietery preparation
  • Cough and cold preparations
  • Antiasthmatics
  • Calcium preparations
  • Antihypertensives
  • Antidiabetics

Achievements/ Awards:

  • BAFNA was awarded the WHO GMP in the year 1995.
  • Bagged the ‘Best Supplier Award’ from the State Pharmaceutical Corporation of Sri Lanka on 30th July 2005.
  • Accorded the status of an ‘Export House’ in recognition of its excellent export performance.
  • Received Medicines and Health Care Products Regulatory Agency (MHRA) approval for its Grantlyon facility meant for exports to the UK markets. Bafna was the 35th company in the Indian pharmaceuticals industry (IPI) to receive MHRA approval.
  • 2009 ISO 9001: 2000 Certificate of Registration for Manufacture and Export of Pharmaceutical products
  • MHRA Certificate of GMP Compliances of Manufacturer from Medicines and Healthcare products Regulatory Agency, U.K.
  • 2010 Bafna Pharmaceuticals have been awarded the Gold Quality Excellence Award 2009
  • Bafna Pharmaceuticals have inaugurated its Formulation Research & Development unit (Formulation Facility) in Chennai
  • 2011 Bafna Pharmaceuticals has received Indian Drug Manufacturer's Association (IDMA) Quality Excellence Award 2010 - Silver Award under the category of Formulations Units
  • Bafna Pharmaceuticals has received Udyog Rattan Award and Excellence Award from the Institute of Economic Studies Delhi.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Loading...
Hold on